Advances in monoclonal antibody technology: Genetic engineering of mice, cells, and immunoglobulins

ILAR Journal

Volumn 46, Issue 3, 2005, Pages 314-319

  Peterson, Norman C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Antibody; Apoptosis; Hybridoma; Immunotherapy; Single chain Fv; Tissue culture

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; PEXELIZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANAPHYLAXIS; ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TESTING REPLACEMENT; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RESEARCH; GENETIC ENGINEERING; HEART INFARCTION; HUMAN; HYBRIDOMA CELL CULTURE; IMMUNOGENICITY; MYELOMA CELL; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; REVIEW; SOLID TUMOR;

ANIMALIA;

EID: 21044448841     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.46.3.314     Document Type: Review

References (48)

1. Berezov A, Zhang HT, Greene MI, Murali R. 2001. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis. J Med Chem 44:2565-2574.
2. Bierau H, Perani A, al-Rubeai M, Emery AN. I998. A comparison of intensive cell culture bioreactors operating with hybridomas modified for inhibited apoptotic response. J Biotechnol 62:195-207.
3. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. 2004. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109:281-290.
4. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. 1997. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. Embo J 16:968-977.
5. Chen K, Liu Q, Xie L, Sharp PA, Wang DI. 2001. Engineering of a mammalian cell line for reduction of lactate formation and high monoclonal antibody production. Biotechnol Bioeng 72:55-61.
6. Chester KA, Bhatia J, Boxer G, Cooke SP, Flynn AA, Huhalov A, Mayer A, Pedley RB, Robson L, Sharma SK, Spencer DI, Begent RH. 2000. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Markers 16:53-62.
7. Choi TK, Hollenbach PW, Pearson BE, Ueda RM, Weddell GN, Kurahara CG, Woodhouse CS, Kay RM, Loring JF. 1993. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome. Nat Genet 4:117-123.
8. Chung JD, Sinskey AJ, Stephanopoulos G. 1998. Growth factor and bcl-2 mediated survival during abortive proliferation of hybridoma cell line. Biotechnol Bioeng 57:164-171.
9. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U. 2003. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9:2837-2848.
10. Drebin JA, Link VC, Greene MI. 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2:387-394.
11. Figueroa B Jr, Sauerwald TM, Mastrangelo AJ, Hardwick JM, Betenbaugh MJ. 2001. Comparison of Bcl-2 to a Bcl-2 deletion mutant for mammalian cells exposed to culture insults. Biotechnol Bioeng 73:211-222.
12. Gauthier ER, Piche L, Lemieux G, Lemieux R. 1996. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res 56:1451-1456.
13. Graus YF, Verschuuren JJ, Degenhardt A, van Breda Vriesman PJ, De Baets MH, Posner JB, Burton DR, Dalmau J. 1998. Selection of recombinant anti-HuD Fab fragments from a phage display antibody library of a lung cancer patient with paraneoplastic encephalomyelitis. J Neuroimmunol 82:200-209.
14. Hansen MH, Nielsen H, Ditzel HJ. 2001. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 98:12659-12664.
15. Holliger P, Prospero T, Winter G. 1993. "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 90:6444-6448.
16. Ishaque A, Al-Rubeai M. 1998. Use of intracellular pH and annexin-V flow cytometric assays to monitor apoptosis and its suppression by bcl-2 over-expression in hybridoma cell culture. J Immunol Methods 221: 43-57.
17. Itoh Y, Ueda H, Suzuki E. 1995. Overexpression of bcl-2, apoptosis suppressing gene: Prolonged viable culture period of hybridoma and enhanced antibody production. Biotechnol Bioeng 48:118-122.
18. Kellermann SA, Green LL. 2002. Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 13:593-597.
19. Kikuchi Y, Uno S, Yoshimura Y, Otabe K, Iida S, Oheda M, Fukushima N, Tsuchiya M. 2004. A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells. Biochem Biophys Res Commun 315:912-918.
20. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, McIntyre GD. 1997. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 16: 381-389.
21. Knott CL, Reed JC, Bodrug S, Saedi MS, Kumar A, Kuus-Reichel K. 1996. Evaluation of Bcl-2/B cell transgenic mice (B6) for hybridoma production. Hybridoma 15:365-371.
22. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
23. Korn T, Muller R, Kontermann RE. 2004. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 27:99-106.
24. Kortt AA, Lah M, Oddie GW, Gruen CL, Burns JE, Pearce LA, Atwell JL, McCoy AJ, Howlett GJ, Metzger DW, Webster RG, Hudson PJ. 1997. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng 10:423-433.
25. Kortt AA, Malby RL, Caldwell JB, Gruen LC, Ivancic N, Lawrence MC, Howlett GJ, Webster RG, Hudson PJ, Colman PM. 1994. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 221:151-157.
26. Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, Knott JG, Duteau A, Goldsby RA, Osborne BA, Ishida I, Robl JM. 2002. Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol 20:889-894.
27. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. 1999. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding. FEBS Lett 453:164-168.
28. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581-897.
29. Murali R, Greene MI. 1998. Structure-based design of immunologically active therapeutic peptides. Immunol Res 17:163-169.
30. Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, Humphries S, Ayling C, Goyenechea B, Xian J, Taussig MJ, Neuberger MS, Bruggemann M. 1999. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol 163:6898-6906.
31. Pasqualini R, Arap W. 2004. Hybridoma-free generation of monoclonal antibodies. Proc Natl Acad Sci U S A 101:257-259.
32. Peterson NC. 1996. Recombinant antibodies: Alternative strategies for developing and manipulating murine-derived monoclonal antibodies. Lab Anim Sci 46:8-14.
33. Peterson NC, Greene MI. 1998. Bacterial expression and characterization of recombinant biologically active anti-tyrosine kinase receptor antibody forms. DNA Cell Biol 17:1031-1040.
34. Pini A, Bracci L. 2000. Phage display of antibody fragments. Curr Protein Pept Sci 1:155-169.
35. Ray S, Diamond B. 1994. Generation of a fusion partner to sample the repertoire of splenic B cells destined for apoptosis. Proc Natl Acad Sci U S A 91:5548-5551.
36. Ritter G, Cohen LS, Williams C, Jr, Richards EC, Old LJ, Welt S. 2001. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61:6851-6859.
37. Russell WMS, Burch RL. 1959. The Principles of Humane Experimental Technique. London: Methuen & Co., LTD. [Reissued: 1992, Universities Federation for Animal Welfare, Herts, England.] Online (http://altweb.jhsph.edu/publications/human-exp/het=toc.htm).
38. Schmidt M, Wels W. 1996. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Br J Cancer 74:853-862.
39. Simpson NH, Milner A, Al-Rubeai M. 1997. Prevention of hybridoma cell death by BCL-2 during suboptimal culture conditions. Biotechnol Bioeng 54:1-16.
40. Simpson NH, Singh RP, Emery AN, Al-Rubeai M. 1999. Bcl-2 over-expression reduces growth rate and prolongs G1 phase in continuous chemostat cultures of hybridoma cells. Biotechnol Bioeng 64:174-186.
41. Simpson NH, Singh RP, Perani A, Goldenzon C, Al-Rubeai M. 1998. In hybridoma cultures, deprivation of any single amino acid leads to apoptotic death, which is suppressed by the expression of the bcl-2 gene. Biotechnol Bioeng 59:90-98.
42. Stockwin LH, Holmes S. 2003. Antibodies as therapeutic agents: Vive la renaissance! Expert Opin Biol Ther 3:1133-1152.
43. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 88:8661-8665.
44. Takahashi N, Kakinuma H, Hamada K, Shimazaki K, Yamasaki Y, Matsushita H, Nishi Y. 2000. Improved generation of catalytic antibodies by MRL/MPJ-lpr/lpr autoimmune mice. J Immunol Methods 235:113-120.
45. Tomizuka K, Yoshida H, Uejima H, Kugoh H, Sato K, Ohguma A, Hayasaka M, Hanaoka K, Oshimura M, Ishida I. 1997. Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat Genet 16:133-143.
46. Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, Mojcik CF, Rollins SA, Levy JH. 2004. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 291:2319-2327.
47. Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. 2004. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 1663:158-166.
48. Wijkhuisen A, Tymciu S, Fischer J, Alexandrenne C, Creminon C, Frobert Y, Grassi J, Boquet D, Conrath M, Couraud JY. 2003. Pharmacological properties of peptides derived from an antibody against the tachykinin NKI receptor for the neuropeptide substance P. Eur J Pharmacol 468: 175-182.